AI
ByIs the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Aspira Women’s Health and Cleveland Clinic’s New AI Alliance Rewrite the Rules for Women’s Diagnostics Across Ovarian Cancer and Beyond?
Key Highlights A Strategic Alliance Built for Scale Aspira Women’s Health and Cleveland Clinic have entered a comprehensive…
Will Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
With the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio Bring Earlier Answers to Patients 55 and Older?
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record in China Rewrite the Global Timeline for Bringing New Medicines to Patients?
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s disclosure that it…
